Scarica l'app Stockscreener
1.99
1.99%
-0.02
Precedente Chiudi:
$2.01
Aprire:
$2.02
Volume 24 ore:
52,645
Relative Volume:
0.54
Capitalizzazione di mercato:
$12.31M
Reddito:
$743.00K
Utile/perdita netta:
$-7.63M
Rapporto P/E:
-0.846
EPS:
-2.3523
Flusso di cassa netto:
-
1 W Prestazione:
-1.01%
1M Prestazione:
-32.76%
6M Prestazione:
-19.76%
1 anno Prestazione:
-7.94%
Intervallo 1D:
$1.97
$2.0438
Intervallo di 1 settimana:
$1.90
$2.11
Portata 52W:
$1.8661
$4.69
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Nome
Can-Fite Biopharma Ltd ADR
Settore
Industria
Telefono
972 3 924 1114
Indirizzo
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Confronta CANF con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| CANF | 1.98 | 12.31M | 743.00K | -7.63M | 0 | -2.3523 |
| VRTX | 449.81 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.30 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 595.77 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.16 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.17 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2017-08-11 | Iniziato | Maxim Group | Buy |
| 2016-10-19 | Ripresa | ROTH Capital | Buy |
| 2016-08-29 | Ripresa | Rodman & Renshaw | Buy |
| 2015-11-30 | Reiterato | H.C. Wainwright | Buy |
| 2015-03-31 | Reiterato | H.C. Wainwright | Buy |
| 2015-03-30 | Downgrade | ROTH Capital | Buy → Neutral |
| 2014-12-29 | Reiterato | ROTH Capital | Buy |
| 2014-11-18 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Can-Fite Biopharma Ltd ADR Borsa (CANF) Ultime notizie
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial - GlobeNewswire Inc.
Can-Fite secures Australian patent for obesity treatment - Investing.com
Can-Fite's partner Vetbiolix secures $325M deal for dog arthritis drug - Investing.com India
Ratios in Focus: Analyzing Can-Fite Biopharma Ltd ADR (CANF)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What is CANF’s price-to-sales ratio telling us about the company’s value? - US Post News
Taking on analysts’ expectations and winning: Can-Fite Biopharma Ltd ADR (CANF) - SETE News
Analytical Lens: Exploring Can-Fite Biopharma Ltd ADR (CANF)’s Financial Story Through Ratios - The Dwinnex
CANF (Can-Fite Biopharma Ltd ADR) has impressive results - US Post News
List of Israeli Stocks Traded on the NYSE Worth Considering - The Times of Israel
Wearable Devices Ltd. sets annual meeting for September 26 - Investing.com
Can-Fite BioPharma shares upgraded by EF Hutton to Buy on pipeline drugs - Investing.com
GitLab stock maintains buy rating on new release By Investing.com - Investing.com
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat - Yahoo New Zealand News
Canine arthritis treatment shows promise in clinical study - Investing.com India
Can-Fite reveals adiponectin role in cancer treatment By Investing.com - Investing.com
Was Can-Fite Biopharma Ltd ADR (CANF)'s session last reading good? – US Post News - US Post News
Can-Fite's Namodenoson gains FDA Fast Track for liver cancer - Investing.com India
Can-Fite's Namodenoson gains FDA Fast Track for liver cancer By Investing.com - Investing.com
Can-Fite's Namodenoson advances in Phase III liver cancer trial By Investing.com - Investing.com
Can-Fite BioPharma seeks FDA nod for NASH drug trial By Investing.com - Investing.com
ANVS Stock Quote Price and Forecast - CNN
symbol__ Stock Quote Price and Forecast - CNN
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire
Can-Fite Announces ADS Ratio Change - Business Wire
Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates - Nasdaq
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma - Business Wire
Best Penny Stocks Today | Penny Stocks to Buy Now -TipRanksTipRanks.com - TipRanks
The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Trea - Benzinga
Can-Fite BioPharma (CANF) Stock Price, News & Analysis - MarketBeat
The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And Mo - Benzinga
32 Stocks Moving In Thursday's Mid-Day SessionAEterna Zentaris (NASDAQ:AEZS), ADMA Biologics (NASDAQ:A - Benzinga
10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance
The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax OfferingiShares B - Benzinga
Secondary Offerings Put A Pause On May's MomentumMynd.ai (AMEX:MYND), Can Fite Biofarma (AMEX:CANF) - Benzinga
28 Stocks Moving In Monday's Pre-Market Session - Benzinga
20 Biggest Mid-Day Gainers For TuesdayAlcoa (NYSE:AA), Biogen (NASDAQ:BIIB) - Benzinga
Can-Fite's Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III Trial For $40 Billion Market (NYSE:CANF) - Seeking Alpha
Propanc Health Group Corp : This Company Could Be the Next CETX or CANF - Marketscreener.com
Morning Market GainersCan Fite Biofarma (AMEX:CANF) - Benzinga
Can-Fite BioPharma Begins Trading in U.S. through Launch of ADRs - CNBC
Can-Fite Biopharma Ltd ADR Azioni (CANF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):